Skip to main content
Sarepta Therapeutics, Inc. logo

Sarepta Therapeutics, Inc. — Investor Relations & Filings

Ticker · SRPT ISIN · US8036071004 LEI · 549300IKDPIED8J8IG21 US Manufacturing
Open in API
Filings indexed 1,061 across all filing types
Latest filing 2022-11-02 Interim / Quarterly Rep…
Country US United States of America
Listing US SRPT

About Sarepta Therapeutics, Inc.

https://www.sarepta.com/

Sarepta Therapeutics is a commercial-stage biopharmaceutical company that engineers precision genetic medicines for rare diseases. The company's research and development efforts are centered on RNA-targeted therapeutics and gene therapies, with a primary focus on treating rare neuromuscular and central nervous system disorders. Sarepta aims to accelerate the drug development process from discovery to patient application and is building significant gene therapy manufacturing capabilities to support its mission.

Recent filings

Filing Released Lang Actions
10-Q
Interim / Quarterly Report Q3 2022
2022-11-02 English
8-K
Capital/Financing Update Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The content describes the entry into a material definitive agreement related to the issuance of convertible senior notes, including purchase agreements, indenture details, and capped call transactions. This is a clear update on the company's financing activities and capital structure changes. It is not a full financial report, earnings release, or management discussion, but rather a disclosure of a significant capital raising transaction. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length and detail support a high confidence in this classification.
2022-09-19 English
FORM 4 SUBMISSION
Director's Dealing
2022-09-15 English
FORM 4 SUBMISSION
Director's Dealing
2022-09-14 English
FORM 4 SUBMISSION
Director's Dealing
2022-08-22 English
S-8
Share Issue/Capital Change Classification · 100% confidence The document is a Form S-8 Registration Statement filed with the SEC, which is used to register securities to be offered under employee benefit plans such as equity incentive plans. It includes details about the registration of additional shares under the 2018 Equity Incentive Plan, signatures of officers and directors, and exhibits related to the plan and legal opinions. There are no financial statements or earnings data, nor is this a report or announcement of financial results. It is a capital market filing related to share issuance under an equity plan. According to the filing definitions, announcements or filings related to new share issues or capital changes fall under the category 'Share Issue/Capital Change' (SHA). Therefore, this document is best classified as SHA.
2022-08-02 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.